TR201802543T4 - Telomeraz aktivitesinin artırılması ve hıv enfeksiyonunun tedavi edilmesi için bileşimler. - Google Patents
Telomeraz aktivitesinin artırılması ve hıv enfeksiyonunun tedavi edilmesi için bileşimler. Download PDFInfo
- Publication number
- TR201802543T4 TR201802543T4 TR2018/02543T TR201802543T TR201802543T4 TR 201802543 T4 TR201802543 T4 TR 201802543T4 TR 2018/02543 T TR2018/02543 T TR 2018/02543T TR 201802543 T TR201802543 T TR 201802543T TR 201802543 T4 TR201802543 T4 TR 201802543T4
- Authority
- TR
- Turkey
- Prior art keywords
- compositions
- telomerase
- hiv infection
- cells
- telomerase activity
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 7
- 208000031886 HIV Infections Diseases 0.000 title claims abstract 4
- 208000037357 HIV infectious disease Diseases 0.000 title claims abstract 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title claims abstract 4
- 108010017842 Telomerase Proteins 0.000 title abstract description 27
- 230000000694 effects Effects 0.000 title abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims description 8
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims description 8
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims description 8
- WENNXORDXYGDTP-UOUCMYEWSA-N cycloastragenol Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O)C4(C)C)[C@H]4[C@@H](O)C[C@H]3[C@]2(C)C[C@@H]1O WENNXORDXYGDTP-UOUCMYEWSA-N 0.000 claims description 6
- WENNXORDXYGDTP-UHFFFAOYSA-N cyclosiversigenin Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CCC34CC4(CCC(O)C4(C)C)C4C(O)CC3C2(C)CC1O WENNXORDXYGDTP-UHFFFAOYSA-N 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- KNESISUQBYQIIU-UHFFFAOYSA-N 6-Angeloyl-1,6-Dihydroxyfuranoeremophilan-9-one Natural products O1C(C(C)(O)C)CCC1(C)C1C2(C)CC=C3C4(C)CCC(O)C(C)(C)C4C(O)CC3C2(C)CC1O KNESISUQBYQIIU-UHFFFAOYSA-N 0.000 claims description 2
- KZGXEJKMJNLRSF-UHFFFAOYSA-N Astragenol Natural products CC(C)(O)C1CCC(C)(O1)C2C(O)CC3(C)C4CC(O)C5(C)C(C)(C)C(O)CCC5(C)C4=CCC23C KZGXEJKMJNLRSF-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 150000008505 β-D-glucopyranosides Chemical group 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 14
- 230000035755 proliferation Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000002417 nutraceutical Substances 0.000 abstract 1
- 235000021436 nutraceutical agent Nutrition 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 108091035539 telomere Proteins 0.000 description 9
- 210000003411 telomere Anatomy 0.000 description 9
- 102000055501 telomere Human genes 0.000 description 9
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 229930182490 saponin Natural products 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100032938 Telomerase reverse transcriptase Human genes 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241001229621 Astragalus verrucosus Species 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010085330 Estradiol Receptors Proteins 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 241000168720 Panax japonicus Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000002556 adrenal cortex cell Anatomy 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003602 anti-herpes Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229930187083 argentatin Natural products 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 150000001928 cycloartanes Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008995 epigenetic change Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000000321 herbal drug Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008943 replicative senescence Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
Abstract
Mevcut buluş hücrelerde telomeraz aktivitesinin artırılması için yöntemler ve bileşimler ile ilgilidir. Bu tür bileşimler, topikal dahil farmasötik bileşimleri, ve nutrasötik bileşimleri içerir. Yöntemler ve bileşimler, bir hastanın hücresinde veya dokusunda telomeraz aktivitesindeki bir artış ile tedaviye tabi, örneğin, HIV enfeksiyonu, çeşitli dejeneratif hastalıklar, ve akut ve kronik deri rahatsızlıkları gibi hastalıkların tedavi edilmesinde faydalıdır. Bunlar, aynı zamanda, ex vivo hücre terapisi ve kök hücrelerin proliferasyonları gibi, kültür içerisindeki hücrelerin replikasyon kapasitesinin artırılmasında faydalıdır.
Description
Tarifname içerisinde atifta bulunulan patent dökümanlari:
Tarifnamede belirtilen patentlestirilmemis literatür:
° ALLSOPP, R.C. et al. Telomere
shortening is associated With cell
division in vitro and in vivo. Exp. Cell
Res., September 1995, vol. 220 (1),
° ALLSOPP, R.C. et al. Telomerase is
required to slow telomere shortening
and extend replicative lifespan of HSC
during serial transplantation. Blood (e-
° BODNAR, A.G. et al. Extension of
life-span by introduction of telomerase
into normal human cells. Science, 16
° CHIU, C.P. et al. Replicative
senescence and cell immortality: the
role of telomeres and telomerase. Proc.
Soc. Exp. Biol. Med., February 1997,
° HARLE-BACHOR, C. et al.
Telomerase activity in the regenerative
basal layer of the epidermis inhuman
skin and in immortal and carcinoma-
derived skin keratinocytes. Proc Natl
Acad Sci USA, 25 June 1996, vol. 93
- HARLEY, C.B. et al. Telomeres
fibroblasts. Nature, 31 May 1990, vol.
° HARLEY, C.B. et al. Telomerase,
cell iminortality, and cancer. Cold
Spring Harb. Symp. Quaiit. Biol.,
- HARLEY, C.B. et al. Telomeres and
telomerase in aging and cancer. Curr.
Opin Genet. Dev., April 1995, vol. 5
and cancer. Important Adv. Oncol.,
o DAGARAG, M. et al. Differential
iinpairment of lytic and cytokine
functions in senescent human
immunodeficiency
virus type 1-specific cytotox T
lymphocytes. J. Virol., March 2003,
- FARWELL, D.G. et al. Genetic and
epigenetic changes in human epithelial
cells immortalized by telomerase.
American Journal of Pathology, May
° FUJIMOTO, R. et al. Expression of
telomerase components in oral
keratinocytes and squamous cell
carcinomas. Oral Oncology, February
o FUNK, WALTER D. et al.
Telomerase expression restores derinal
integrity to in vitro-aged fibroblasts in a
reconstituted skin model. Experimental
Cell Research,
° LEE, K.M. et al. Immortalization
With telomerase of the Nestin-positive
cells of the human pancreas. Biochem
Biophys Res Commun, 21 February
0 LUDWIG, A. et al. Ribozyme
cleavage of telomerase mRNA
sensitizes breast epithelial cells to
inhibitors of topoisomerase. Cancer
Res., 2001, vol. 61,
° MATTSON, M.P. Emerging
neuroprotective strategies for
A12heimer”s disease: dietary restriction,
telomerase
activation, and stem cell therapy. Exp
502 [0005]
- MORALES, C. P. et al. Absence of
cancer-associated changes in human
fibroblasts immortalized With
telomerase. Nature Genetics, January
1999, vol. 21
(1), 115-8 [0005]
telomeres. Ciba Found. Symp., 1997,
- HARLEY, C.B. Telomerase is not an
° HENDERSON, S. et :11. In situ
analysis of changes in telomere size
during replicative aging and cell
transformation. J. Cell Biol., July 1996,
o JIANG, X.R. et al. Telomerase
expression in human somatic cells does
not induce changes associated
with a transformed phenotype. Nature
Genetics, January 1999, vol. 21 (1),
1 1 1-4 [0005]
- KANG, M.K. et al. Replicative
senescence of normal human oral
keratinocytes is associated With the loss
shortening of telomeres. Cell Growth &
Differentiation, January 1998, vol.
effects of ginsenoside-Rgl on p561ck
kinase and cell proliferation in
J urkat T cells. Korean J. Ginseng Sci.,
- Selected non-timber forest products
With medicinal applications from J ilin
Province in China. HUANG, Y.
et al. Conference Title: Forest
communities in the third millennium:
Linking research, business, and policy
toward a sustainable non-timber forest
product sector; Kenora, Ontario,
Canada, 1-4 October, 1999. General
Research Station, USDA Forest
. KANEKO, M. et al. Accelerated
recovery from cyclophosphamide-
induced leukopenia in mice
administered a Japanese ethical herbal
drug, Hochu-ekki-to.
lmmunopharmacology, 1999, vol. 44
0 OH, H. ; SCHNEIDER, MD. The
emerging role of telomerase in cardiac
muscle cell growth and survival. J Mol
Cell Cardiol, July 2002, vol. 34 (7),
717-24 [0005]
° SIMONSEN, J.L. et al. Telomerase
expression extends the proliferative
life-span and maintains the osteogenic
stromal
cells. Nat Biotechnol, June 2002, vol.
o THOMAS, M. ; YANG, L. ;
functional tissue from transplanted
adrenocortical
cells expressing telomerase reverse
transcriptase. Nat Biotechnol, January
activates telomerase and delays
endothelial cell senescence. Circ. Res.,
° YANG, J. et al. Telomerized human
microvasculature is functional in vivo.
Nature Biotechnology (United States),
- YANG, J. et al. Human endothelial
cell life extension by telomerase
expression. J. Biol. Chein., 10
- YUDOH, K. et al. Reconstituting
telomerase activity using the telomerase
catalytic subunit prevents the telomere
shorting and replicative senescence in
human osteoblasts. J. Bore and Mineral
0 BEDIR, E. et al. lmmunostimulatory
effects of cycloartane-type triterpene
glycosides from Astragalus Species.
Biol & Pharm Bull, 2000, vol. 23 (7),
834-7
tetracyclic triterpenes (argentatins A, B
and D) on the estradiol receptor of
- KINJO, J. et al. Anti-herpes virus
activity of fabaceous triterpenoidal
saponins. Biological pharinaceutical
- KHUSHBAKTOVA, Z. A. et al.
lnfluence of cycloartanes from plants of
synthetic analogs on the contractive
function of the myocarbium and the
activity 0fNa,K-ATPase. Chem. Nat.
- LEE, Y.J. et al. Ginsenoside-Rgl,
one of the major active molecules from
Panax ginseng, is a functional ligand of
glucocorticoid receptor. Mol Cell
Endocrinol, October 1997, vol. 133 (2),
135-40 [0007]
- LIU, P. et al. Effect of ginsenosides
Rbl , Rgl, Rhl and Re en proliferation
of cells in vitro. Tianran Chanwu
haemolytic activities of 47 saponins
derived from medicinal and food plants.
- PISTELLI, L. et al. Antimicrobial
and antifungal activity of crude extracts
and isolated saponins from Astragalus
verrucosus. Fitoterapia, 2002, vol. 73
ginsenoside Re on the proliferation of
murine bone marrow cells. Baiqiuen
Yike Daxue Xuebao, 1997, vol. 23 (2),
- WANG, Y-P. et al. Effect of
astragaloside IV on T,B lymphocyte
proliferation and peritoneal macrophage
function in mice. Acta Pharmacologica
triterpene derivatives from plants
hormone-dependent tumors of human
breast. Medical Science Research,
0 CHEN, X. et al. Protective effect of
ginsenoside Rgl on dopamin-induced
apoptotis in PC12 cells. Acta
Pharmacol Sinica, 2001, vol. 22 (8),
° ZHANG W.J. et al. Regulation of the
fibrinolytic potential of cultured human
umbilical vein endothelial cells:
astragaloside IV downregulates
plasminogen activator inhibitor-l and
upregulates tissue-type plasminogen
activator expression. Journal of
Vascular
80 [0007]
0 ZI-PU, L. ; QIAN, C. Effects of
astragaloside IV on myocardial calcium
transport and cardiac function in
ischemic rats. Acta Pharmacol Sin,
° ROKIA et al. Pharmazie, 1993, vol.
0 LONKOVA. Phytochemistry, 1997,
inhibit the effects of a tumor promoter,
and sitostero] and betulinic acid inhibit
tumor formation in mouse skin two-
Stage carcinogenesis. Oncology,
stimulatory effects of ginseng saponins
on proliferation and DNA synthesis of
human vascular endothelial cells and
skin fibroblasts in relation to cytokines
or growth factors. Nissei Byoin Igaku
o P-H WANG et al. J. Chinese Chem.
° OH; SCHNEIDER.J Mol Cell
- MATTSON. Exp Gerontol., vol. 35
- SIMONSEN et al. Nat Biotechnol,
- THOMAS et al. Nat Biotechnol,
Sciences. Williams & Wilkins, 1995
SEKILLERDEKI YAZILARIN ANLAMLARI
A : Astragalosid IV
B = Astragenol
C = Sikloastragenol
D = Astragalosid IV 16-011
E : Ginsenosid RHl
F :1 Bilesiginin Insan Keratinositlerinde Telomeraz Aktivitesi
Üzerindeki Etkisi
G = Telomeraz Aktivitesi (% KTRL)
H = Konsantrasyon (ug/ml)
Üzerindeki Etkisi
J :Doz (HM)
K = Yaslanan Eriskin Keratinositlerde Yara Iyilesmesinin Hizlanmasi
L = Kontrol
R = Genç Keratinositlerde Yara Iyilesmesinin Hizlanmasi
S = Yaslanan Keratinositlerde Yara Iyilesmesinin Hizlanmasi
T :Yaslanan Keratinositlerde Yara Iyilesmesi
U = Açik Yara (% KTRL)
9 &ama
N 1555
0.. Nm v de To Nmoö 5.0 Nmood
Awimon. m0& "%555
.ninbvmâkân ü
8:20 + g.. __2 giii
even_ mâxmllol
Claims (5)
1. Formül 1 ile gösterilen, bir HIV enfeksiyonun tedavisinde kullanim amaçli, etkili miktarda izole bir bilesik olup: X1, hidroksidir veya ß-D-glukopiranoziddir, 10 X2, hidroksidir veya ß-D-glukopiranoziddir, ve X3, hidroksidir; OR', hidroksidir; R2, 9. karbon ile birlikte kayiiasmis bir siklopropil halkasi 15 olusturur; ve 2 9. ve 11. karbonlar arasindaki bir tekli bagi gösterir.
2. Bir HIV enfeksiyonun tedavisinde kullanim amaçli, etkili miktarda astragalosid IV 16-0ndur.
3. Bir farmas'otik bilesim olup, söz konusu bilesim, farmasötik açidan kabul edilebilir bir tasiyici içerisinde, astragalosid IV 16-011, sikloastragenol 6-ß-D-glukopiranozid ve sikloastragenol 3-ß-D- ksilopiranozid içerisinden seçilen bir bilesigi içerir.
4. Bir farmasötik bilesim olup, söz konusu bilesim, sikloastragenol, astragenol, astragalosid IV 16-0n, sikloastragenol 6-ß-D- glukopiranozid ve sikloastragenol 3-ß-D-ksilopiranozid içerisinden seçilen izole bir bilesigin bir topikal formülasyonunu içerir.
5. Istem 4'e göre bilesim olup, burada, söz konusu bilesik belirtilen formülasyonda en az %0,1 (agirlik/hacim) konsantrasyonunda bulunur.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48098803P | 2003-06-23 | 2003-06-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201802543T4 true TR201802543T4 (tr) | 2018-03-21 |
Family
ID=33551962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/02543T TR201802543T4 (tr) | 2003-06-23 | 2004-06-23 | Telomeraz aktivitesinin artırılması ve hıv enfeksiyonunun tedavi edilmesi için bileşimler. |
| TR2019/03587T TR201903587T4 (tr) | 2003-06-23 | 2004-06-23 | Telomeraz aktivitesinin artırılması için bileşimler. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/03587T TR201903587T4 (tr) | 2003-06-23 | 2004-06-23 | Telomeraz aktivitesinin artırılması için bileşimler. |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US7846904B2 (tr) |
| EP (2) | EP1644009B1 (tr) |
| JP (4) | JP5583882B2 (tr) |
| KR (3) | KR101465515B1 (tr) |
| CN (1) | CN1809364B (tr) |
| AP (1) | AP2280A (tr) |
| AU (2) | AU2004251753C1 (tr) |
| BR (1) | BRPI0411856A (tr) |
| CA (1) | CA2528483C (tr) |
| CY (2) | CY1119951T1 (tr) |
| DK (2) | DK2548880T3 (tr) |
| EA (1) | EA009442B1 (tr) |
| ES (2) | ES2716528T3 (tr) |
| HR (2) | HRP20180330T1 (tr) |
| HU (2) | HUE043168T2 (tr) |
| LT (2) | LT1644009T (tr) |
| MX (1) | MXPA05013844A (tr) |
| NZ (1) | NZ544191A (tr) |
| PL (2) | PL1644009T3 (tr) |
| PT (2) | PT2548880T (tr) |
| SI (2) | SI1644009T1 (tr) |
| TR (2) | TR201802543T4 (tr) |
| WO (1) | WO2005000245A2 (tr) |
| ZA (1) | ZA200509846B (tr) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7585622B1 (en) | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
| US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
| CN1809364B (zh) * | 2003-06-23 | 2010-06-16 | 杰龙公司 | 增加端粒酶活性的组合物和方法 |
| WO2005000248A2 (en) * | 2003-06-25 | 2005-01-06 | Geron Corporation | Compositions and methods for skin conditioning |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| US8197860B2 (en) * | 2005-06-23 | 2012-06-12 | Nuliv Holding Inc. | Method for enhancing nutrient absorption with astragalosides |
| CN100333731C (zh) * | 2005-09-08 | 2007-08-29 | 南京医科大学 | 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用 |
| CN100384830C (zh) * | 2006-01-12 | 2008-04-30 | 天津药物研究院 | 环黄芪醇类衍生物以及用途 |
| US7992749B2 (en) | 2006-03-30 | 2011-08-09 | Nike, Inc. | Support element for a carry strap |
| EP2898887B1 (en) | 2006-10-30 | 2018-09-26 | Geron Corporation | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
| MX2009013354A (es) * | 2007-06-04 | 2010-07-06 | Univ Ben Gurion | Compuestos de triarilo y composiciones que los contienen. |
| CN101225424B (zh) * | 2007-09-13 | 2013-05-29 | 天津药物研究院 | 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用 |
| US8168596B2 (en) * | 2008-10-17 | 2012-05-01 | Nuliv Holding Inc. | Use of cycloartane compounds for treating arthritis |
| CA2795981C (en) * | 2009-05-18 | 2017-06-27 | Geron Corporation | Compositions and methods for increasing telomerase activity |
| US20160081912A1 (en) * | 2013-05-15 | 2016-03-24 | Fybrands Corp. | Compositions for improving the hair, skin, and nails |
| AU2014347668A1 (en) | 2013-11-05 | 2016-05-19 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
| CN104435371A (zh) * | 2014-12-06 | 2015-03-25 | 郭亮 | 一种用于治疗关节炎的药酒 |
| CN104491185A (zh) * | 2014-12-06 | 2015-04-08 | 郭亮 | 一种祛风湿药酒及其制备方法 |
| CN104435370A (zh) * | 2014-12-06 | 2015-03-25 | 王香平 | 风湿保健酒 |
| KR20160069857A (ko) | 2014-12-09 | 2016-06-17 | (주)스피어테크 | 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법 |
| CN104817610A (zh) * | 2015-03-15 | 2015-08-05 | 北京化工大学 | 利用硫酸水解制备环黄芪醇的方法 |
| US10100285B2 (en) | 2015-04-03 | 2018-10-16 | Propagenix Inc. | Ex vivo proliferation of epithelial cells |
| SG11201707970XA (en) | 2015-04-03 | 2017-10-30 | Propagenix Inc | Ex vivo proliferation of epithelial cells |
| CN106474094A (zh) * | 2015-08-31 | 2017-03-08 | 南京理工大学 | 一种环黄芪醇电纺纤维膜及其制备方法 |
| CA2998372A1 (en) | 2015-09-11 | 2017-03-16 | Chengkang ZHANG | Ex vivo proliferation of epithelial cells |
| CN106307522A (zh) * | 2016-11-06 | 2017-01-11 | 谭淞文 | 一种抗衰老保健品及其制备方法和食用方法 |
| CN106831927B (zh) * | 2017-02-07 | 2018-02-09 | 江西师范大学 | 一种黄芪甲苷的合成方法 |
| CN108498521B (zh) * | 2017-02-24 | 2020-05-05 | 北京大学 | 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用 |
| US10098922B1 (en) | 2017-11-30 | 2018-10-16 | Optigenex, Inc. | Increasing telomere length in a cell |
| WO2020028055A1 (en) * | 2018-07-31 | 2020-02-06 | ADLER, Benjamin, Aaron | Ophthalmic formulations and uses thereof |
| CN111053782A (zh) | 2018-10-17 | 2020-04-24 | 株式会社爱茉莉太平洋 | 包含新型人参皂苷的组合物 |
| KR102635196B1 (ko) | 2018-10-17 | 2024-02-13 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 미백 조성물 |
| US11000538B2 (en) | 2018-10-31 | 2021-05-11 | Amorepacific Corporation | Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside |
| WO2020131058A1 (en) * | 2018-12-20 | 2020-06-25 | Muhammed Majeed | Telomerase enhancement potential of ecdysterone |
| CN109942663B (zh) * | 2019-04-22 | 2021-10-26 | 中国人民解放军联勤保障部队第九八九医院 | 利用双相酸水解制备环黄芪醇的方法 |
| MX2019006749A (es) | 2019-06-10 | 2022-11-28 | Univ Mexico Nac Autonoma | Compuestos activadores de senescencia celular. |
| KR20210037256A (ko) | 2019-09-27 | 2021-04-06 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물 |
| KR20210037257A (ko) | 2019-09-27 | 2021-04-06 | (주)아모레퍼시픽 | 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물 |
| CN111419854B (zh) * | 2020-05-18 | 2021-03-30 | 南通大学 | 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用 |
| CN113480628B (zh) * | 2021-08-17 | 2022-06-21 | 贵州师范大学 | 一种贵州疣螈多肽tk-cath及其编码基因和应用 |
| CN113968894B (zh) * | 2021-11-05 | 2024-05-28 | 山西大学 | 一种用黄芪甲苷降解制备环黄芪醇的方法 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6212792A (ja) * | 1986-07-18 | 1987-01-21 | Osaka Chem Lab | オウギサポニン類の単離法 |
| JPS6212791A (ja) | 1986-07-18 | 1987-01-21 | Osaka Chem Lab | オウギサポニン、その単離法およびその用途 |
| IT1259645B (it) | 1992-04-10 | 1996-03-25 | Solis Srl | Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US6007989A (en) | 1992-05-13 | 1999-12-28 | Board Of Regents, The University Of Texas System | Methods of screening for compounds that derepress or increase telomerase activity |
| FR2695561B1 (fr) | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| JPH07238026A (ja) * | 1994-02-25 | 1995-09-12 | Pola Chem Ind Inc | 動脈硬化抑制剤及びこれを含む食品又は医薬 |
| AT402890B (de) * | 1994-03-16 | 1997-09-25 | Berbi Gmbh | Verwendung von notoginsenosid r1 zur herstellung von arzneimitteln |
| CN1231491C (zh) * | 1994-07-07 | 2005-12-14 | 杰龙公司 | 哺乳动物端粒酶 |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US6162459A (en) | 1995-02-24 | 2000-12-19 | National Science Council | Acyclovir transdermal delivery system |
| AUPN411195A0 (en) | 1995-07-10 | 1995-08-03 | Cathay Herbal Laboratories Pty Ltd | Medicinal composition |
| CN1079265C (zh) | 1995-08-01 | 2002-02-20 | 裴国增 | 灵芝口服液及其配制方法 |
| US5785977A (en) | 1996-02-07 | 1998-07-28 | Breithbarth; Richard | Non-metallic microparticle carrier materials |
| US5916565A (en) | 1996-03-08 | 1999-06-29 | In Clover, Inc. | Product and method for treating joint disorders in vertebrates |
| TW452494B (en) | 1996-03-12 | 2001-09-01 | Jang De Shan | Herbal composition for stimulating blood circulation |
| US5900226A (en) | 1997-04-09 | 1999-05-04 | Uop Llc | Drying agents for non-foamed polyurethanes |
| JPH1036388A (ja) * | 1996-07-25 | 1998-02-10 | Kureha Chem Ind Co Ltd | ジンセノサイド類含有ｈｓｐ４７合成抑制剤 |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6093809A (en) | 1996-10-01 | 2000-07-25 | University Technology Corporation | Telomerase |
| CA2267664C (en) | 1996-10-01 | 2013-06-11 | Geron Corporation | Human telomerase reverse transcriptase |
| US20020044977A1 (en) | 1997-01-28 | 2002-04-18 | Graeme A. Close | Centipeda plant extract |
| US5786343A (en) | 1997-03-05 | 1998-07-28 | Immudyne, Inc. | Phagocytosis activator compositions and their use |
| WO1999012519A1 (en) | 1997-09-05 | 1999-03-18 | The Procter & Gamble Company | Cleansing and conditioning products for skin or hair with improved deposition of conditioning ingredients |
| DE69808790T3 (de) | 1997-09-12 | 2009-07-16 | The Procter & Gamble Co., Cincinnati | Hautreinigungs- und konditionierungsartikel für haut und haar |
| IL137101A0 (en) | 1998-01-12 | 2001-06-14 | Cold Spring Harbor Lab | Extension of cellular lifespan, methods and reagents |
| GB9815177D0 (en) | 1998-07-13 | 1998-09-09 | King S College London | Treatment of skin disorders |
| AU5338199A (en) | 1998-08-09 | 2000-02-28 | Geron Corporation | Methods and compositions for inhibiting or stimulating telomerase assembly |
| CA2352486A1 (en) | 1998-11-25 | 2000-06-02 | Genetica, Inc. | Methods and reagents for increasing proliferative capacity and preventing replicative senescence |
| JP2000204091A (ja) * | 1999-01-13 | 2000-07-25 | Nippon Suisan Kaisha Ltd | 新規ベンゾジオキソ―ル誘導体 |
| JP2000229827A (ja) * | 1999-02-05 | 2000-08-22 | Kose Corp | 皮膚外用剤 |
| JP2000229834A (ja) * | 1999-02-10 | 2000-08-22 | Kanebo Ltd | 化粧料 |
| AUPQ127399A0 (en) * | 1999-06-29 | 1999-07-22 | Guangzhou University Of Traditional Chinese Medicine | Compositions and methods for treating or preventing osteoporosis |
| WO2001018015A1 (en) | 1999-09-10 | 2001-03-15 | Geron Corporation | Oligonucleotide n3'→p5' thiophosphoramidates: their synthesis and use |
| JP2001258505A (ja) * | 2000-03-24 | 2001-09-25 | Fancl Corp | 食品組成物 |
| CA2307393A1 (en) * | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| US6277396B1 (en) | 2000-05-11 | 2001-08-21 | Maximum Human Performance, Inc. | Dietary supplement containing a thermogenic substance and an adrenal support substance |
| WO2001092289A1 (fr) | 2000-05-31 | 2001-12-06 | Japan Science And Technology Corporation | Promoteurs de regeneration de tissu cutane contenant le ginsenoside rb1 |
| CN1172677C (zh) * | 2000-07-14 | 2004-10-27 | 复旦大学附属中山医院 | 黄芪甲苷在制备药物组合物中的应用 |
| GB0105613D0 (en) | 2001-03-07 | 2001-04-25 | Univ Cambridge Tech | Pharmaceutically effective compounds and their use |
| AU2001275707A1 (en) * | 2000-07-26 | 2002-02-05 | Cambridge University Technical Services Limited | Use of panaxatriol for stimulation angiogenesis |
| US6696094B2 (en) | 2000-10-18 | 2004-02-24 | Tzu-Sheng Wu | Herbal pharmaceutical composition for treatment of HIV/AIDS patients |
| CN1242807C (zh) * | 2000-11-08 | 2006-02-22 | 天津市延龄营养保健品有限公司 | 一种抗皮肤过敏的药物组合物及其制法和用途 |
| CN1369276A (zh) | 2001-02-12 | 2002-09-18 | 徐秀荣 | 有效减轻体重的组合物和方法 |
| JP2002275086A (ja) * | 2001-03-15 | 2002-09-25 | Fancl Corp | 虚弱体質改善用組成物 |
| US7262174B2 (en) | 2001-05-09 | 2007-08-28 | Geron Corporation | Treatment for wounds |
| US20020182272A1 (en) | 2001-05-30 | 2002-12-05 | Bruce Halstead | Methods of treatment of HIV-associated conditions |
| US20040180938A1 (en) | 2001-07-03 | 2004-09-16 | Akio Ohtani | Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof |
| JP2003089687A (ja) * | 2001-07-03 | 2003-03-28 | Tanabe Seiyaku Co Ltd | 新規ブタジエン誘導体、その製法およびその合成中間体 |
| US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| US20030108629A1 (en) | 2001-07-17 | 2003-06-12 | Chou Wen Hsien | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| CN1164608C (zh) * | 2001-08-31 | 2004-09-01 | 上海中医药大学 | 具有抗心肌纤维化作用的黄芪皂甙甲 |
| CN1406585A (zh) * | 2001-09-07 | 2003-04-02 | 中国科学院上海药物研究所 | 一种治疗病毒性心肌炎的药物组合物 |
| JP2003160497A (ja) * | 2001-11-22 | 2003-06-03 | Toshin Kagaku Kk | 皮膚外用剤 |
| WO2003066814A2 (en) | 2002-02-04 | 2003-08-14 | Ceremedix, Inc. | Peptide-dependent upregulation of telomerase expression |
| CN1236803C (zh) | 2002-03-20 | 2006-01-18 | 郑国芃 | 一种治疗风湿症的中药 |
| CN1189176C (zh) * | 2002-07-22 | 2005-02-16 | 江苏正大天晴药业股份有限公司 | 黄芪甲甙组合物及其制备方法 |
| WO2004096251A1 (en) * | 2003-03-26 | 2004-11-11 | Westlake Partners | Herbal compositions and methods for effecting weight loss in humans |
| US20070259014A1 (en) * | 2003-06-20 | 2007-11-08 | Vgx Pharmaceuticals, Inc. | Compositions for and Methods for Treating Hiv |
| CN1809364B (zh) | 2003-06-23 | 2010-06-16 | 杰龙公司 | 增加端粒酶活性的组合物和方法 |
| WO2005000248A2 (en) | 2003-06-25 | 2005-01-06 | Geron Corporation | Compositions and methods for skin conditioning |
| WO2005044179A2 (en) | 2003-06-27 | 2005-05-19 | Hong Kong University Of Science And Technology | Formulations containing astragalus extracts and uses thereof |
-
2004
- 2004-06-23 CN CN2004800172464A patent/CN1809364B/zh not_active Expired - Lifetime
- 2004-06-23 KR KR1020137031630A patent/KR101465515B1/ko active IP Right Grant
- 2004-06-23 KR KR1020057024720A patent/KR101312389B1/ko active IP Right Grant
- 2004-06-23 EA EA200600076A patent/EA009442B1/ru unknown
- 2004-06-23 AP AP2005003474A patent/AP2280A/xx active
- 2004-06-23 HU HUE12180710A patent/HUE043168T2/hu unknown
- 2004-06-23 EP EP04777032.6A patent/EP1644009B1/en not_active Expired - Lifetime
- 2004-06-23 LT LTEP04777032.6T patent/LT1644009T/lt unknown
- 2004-06-23 NZ NZ544191A patent/NZ544191A/en unknown
- 2004-06-23 PL PL04777032T patent/PL1644009T3/pl unknown
- 2004-06-23 PT PT12180710T patent/PT2548880T/pt unknown
- 2004-06-23 SI SI200432425T patent/SI1644009T1/en unknown
- 2004-06-23 JP JP2006517617A patent/JP5583882B2/ja not_active Expired - Lifetime
- 2004-06-23 TR TR2018/02543T patent/TR201802543T4/tr unknown
- 2004-06-23 HU HUE04777032A patent/HUE036559T2/hu unknown
- 2004-06-23 BR BRPI0411856-1A patent/BRPI0411856A/pt not_active Application Discontinuation
- 2004-06-23 ES ES12180710T patent/ES2716528T3/es not_active Expired - Lifetime
- 2004-06-23 ES ES04777032.6T patent/ES2666864T3/es not_active Expired - Lifetime
- 2004-06-23 PL PL12180710T patent/PL2548880T3/pl unknown
- 2004-06-23 MX MXPA05013844A patent/MXPA05013844A/es active IP Right Grant
- 2004-06-23 US US10/562,374 patent/US7846904B2/en active Active
- 2004-06-23 LT LTEP12180710.1T patent/LT2548880T/lt unknown
- 2004-06-23 CA CA2528483A patent/CA2528483C/en not_active Expired - Lifetime
- 2004-06-23 PT PT47770326T patent/PT1644009T/pt unknown
- 2004-06-23 DK DK12180710.1T patent/DK2548880T3/en active
- 2004-06-23 EP EP12180710.1A patent/EP2548880B1/en not_active Expired - Lifetime
- 2004-06-23 SI SI200432463T patent/SI2548880T1/sl unknown
- 2004-06-23 WO PCT/US2004/020277 patent/WO2005000245A2/en active Application Filing
- 2004-06-23 ZA ZA200509846A patent/ZA200509846B/en unknown
- 2004-06-23 DK DK04777032.6T patent/DK1644009T3/en active
- 2004-06-23 AU AU2004251753A patent/AU2004251753C1/en not_active Ceased
- 2004-06-23 KR KR1020117017367A patent/KR20110089887A/ko active Application Filing
- 2004-06-23 TR TR2019/03587T patent/TR201903587T4/tr unknown
-
2008
- 2008-11-25 AU AU2008249200A patent/AU2008249200A1/en not_active Abandoned
-
2010
- 2010-03-05 US US12/718,812 patent/US8759304B2/en not_active Expired - Lifetime
-
2011
- 2011-02-21 JP JP2011035191A patent/JP5841337B2/ja not_active Expired - Lifetime
-
2013
- 2013-10-23 JP JP2013219989A patent/JP5913253B2/ja not_active Expired - Lifetime
-
2014
- 2014-06-24 US US14/313,698 patent/US20150093455A1/en not_active Abandoned
-
2016
- 2016-01-04 JP JP2016000130A patent/JP2016041770A/ja not_active Withdrawn
-
2018
- 2018-02-23 HR HRP20180330TT patent/HRP20180330T1/hr unknown
- 2018-02-26 CY CY20181100225T patent/CY1119951T1/el unknown
-
2019
- 2019-02-18 HR HRP20190322TT patent/HRP20190322T1/hr unknown
- 2019-03-22 CY CY20191100342T patent/CY1121447T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201802543T4 (tr) | Telomeraz aktivitesinin artırılması ve hıv enfeksiyonunun tedavi edilmesi için bileşimler. | |
| Wong et al. | Recent advances in ginseng as cancer therapeutics: a functional and mechanistic overview | |
| Huang et al. | Mechanism of mesenchymal stem cell–induced neuron recovery and anti-inflammation | |
| Nowell | Inhibition of human leukocyte mitosis by prednisolone in vitro | |
| Sun et al. | Acanthopanax senticosus polysaccharide suppressing proliferation and metastasis of the human non-small cell lung cancer NCI-H520 cells is associated with Wnt/β-catenin signaling. | |
| KR100874613B1 (ko) | 줄기세포 배양액을 이용한 암세포 성장 저해 방법 | |
| Pessina et al. | Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel | |
| Lemieszek et al. | Anticancer effect of fraction isolated from medicinal Birch polypore mushroom, Piptoporus betulinus (Bull.: Fr.) P. Karst.(Aphyllophoromycetideae): In vitro studies | |
| Dai et al. | Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins | |
| JP2004210784A (ja) | Ｄｉｏｓｃｏｒｅａｓｐ．抽出物およびその医学的使用 | |
| Levavi-Sivan et al. | Exposure of tilapia pituitary cells to saponins: insight into their mechanism of action | |
| JP2005272441A (ja) | Ｄｉｏｓｃｏｒｅａｓｐ．抽出物およびその医学的使用 | |
| JPH06239759A (ja) | 細胞増殖促進物質及びそれを含有する組成物 | |
| Sanecka et al. | Birch Polypore Mushroom, Piptoporus betulinus (Bull.: Fr.) P. Karst.(Aphyllophoromycetideae): In Vitro Studies |